<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00920725</url>
  </required_header>
  <id_info>
    <org_study_id>05012103</org_study_id>
    <nct_id>NCT00920725</nct_id>
  </id_info>
  <brief_title>Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA</brief_title>
  <acronym>DKA</acronym>
  <official_title>Subcutaneous Aspart Insulin and Point of Care Beta Hydroxybutyrate Testing: A New Paradigm for the Management of Diabetic Ketoacidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rush University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether insulin administered by a subcutaneous
      injection is effective in the treatment of a diabetic crisis and to determine if
      beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hours to resolution of ketoacidosis as defined as beta-hydroxybutyrate &lt;0.6</measure>
    <time_frame>q 2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hours to achieve blood glucose less than 200mg/dl</measure>
    <time_frame>q 1 hour</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetic Ketoacidosis</condition>
  <arm_group>
    <arm_group_label>Subcutaneous Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspart Insulin administered subcutaneously 0.2 units/kg/sq every 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV Regular Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Regular Insulin 0.1 units/kg/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Novolog Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Novolog Insulin 0.1 units/kg/hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin (Aspart Insulin [Novolog], Regular Insulin)</intervention_name>
    <description>Aspart Insulin 0.2units/sq q 2 hours
Regular Insulin 0.1units/kg/hr intravenous
Aspart Insulin 0.1 units/kg/hr intravenous</description>
    <arm_group_label>Subcutaneous Insulin</arm_group_label>
    <arm_group_label>IV Regular Insulin</arm_group_label>
    <arm_group_label>Intravenous Novolog Insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: age 18 or older

          -  venous pH &lt; 7.3 or arterial &lt; 7.35

          -  at least 2 of the following 3:

               1. serum HCO3 &lt; 18/anion gap &gt; 16

               2. serum glucose &gt; 300 mg/dl

               3. serum acetone positive

        Exclusion Criteria:

          -  pregnant

          -  less than age 18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rema A Gupta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Baldwin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rush University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2009</study_first_submitted>
  <study_first_submitted_qc>June 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2009</study_first_posted>
  <last_update_submitted>August 14, 2012</last_update_submitted>
  <last_update_submitted_qc>August 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rush University Medical Center</investigator_affiliation>
    <investigator_full_name>David Baldwin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>DKA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

